A phase 1, randomized, double blind, placebo controlled, multiple ascending dose, safety and pharmacodynamic study of MDV1634 in patients with Parkinson*s disease.

MDV1634 is an investigational compound under study as a potential
disease-modifying therapy for Parkinson*s disease. Current drug treatments for
Parkinson*s disease do not cure the disease and are largely aimed at reducing
symptoms by increasing dopamine in the central nervous system (such as
levodopa). MDV1634 is being studied to see if it has neuroprotective properties
in Parkinson*s patients and hence slows progression of the disease.

The main purpose of the study is to investigate the safety and tolerability of
MDV1634. Additional objectives of the study are to assess how quickly and to
what extent MDV1634 is absorbed and eliminated from the body
(pharmacokinetics), and the effect of the compound on disease indicators
(biomarkers) will be explored.

This is a Phase 1, randomized, double-blind, placebo-controlled study in
patients with Parkinson*s disease. The study will evaluate the safety and
tolerability of MDV1634 administered for 21 days at different dose levels in
patients with Parkinson*s disease.

MDV1634 or placebo.

All drugs cause side effects; the extent to which this occurs differs between
drugs. A total of 109 subjects including healthy volunteers and patients with
Parkinson*s disease have received one or more doses of MDV1634. MDV1634 was
generally well tolerated in these studies. The most frequently reported
complaints were headache, diarrhea and dizziness. MDV1634 has the potential to
lower blood pressure, but this has not been observed in any completed studies.
Since the study drug will be administered for only 3 weeks, no significant
health benefits are expected for participants in this study.